
Dec 22 (Reuters) - The U.S. Food and Drug Administration approved Novo Nordisk's NOVOb.CO weight-loss pill on Monday, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly LLY.N.